Tag Archives: Psychiatric Adverse Events

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Posted on February 3, 2016 by Dementia and Elderly Care News

Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards | Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis | Leave a comment